Analysis-South America, battered by COVID-19, now winning global
vaccination race
Send a link to a friend
[December 28, 2021]
By Gram Slattery and Augustin Geist
RIO DE JANEIRO/BUENOS AIRES (Reuters) -
Throughout much of 2020 and early 2021, South America was ground zero in
the global fight against COVID-19.
Oxygen ran low in Peru. Gravediggers worked through the night in Sao
Paulo, Brazil. Bodies were stuffed into shipping containers in
Guayaquil, Ecuador.
Brazil, the largest country in Latin America, saw its COVID-19 death
toll rise to the second-highest in the world, while Argentina and Peru
reported some of the heaviest death per capita figures anywhere.
But in recent months, despite patchy health services and lower income
levels than in Europe or the United States, the region has emerged as a
surprise winner in the vaccination race.

South America is now the most vaccinated region in the world, with 63.3%
of the population fully inoculated, according to the Our World in Data
project, which collects official numbers from governments worldwide.
Europe comes in second with 60.7%. In Africa, just 8.8% of the
population has completed a full vaccination regimen.
Infection and death rates have plummeted compared to the middle of the
year when Latin America and the Caribbean accounted for almost half of
global deaths and infections. Now it is Europe where - due to the spread
of the Omicron variant - contagion is rebounding.
Epidemiologists point to several factors to explain the speedy
vaccination drive. But the most important, they say, has been decades of
successful inoculation campaigns that have created the infrastructure
needed to deliver jabs en masse, while instilling trust among the
population.
In Brazil, successful inoculation drives in the last half century
against smallpox, meningitis, polio and measles means that very few
people are opposed to vaccines, said Paulo Lotufo, an epidemiologist and
professor at the University of Sao Paulo.
In some major cities, including Rio de Janeiro and Sao Paulo, over 99%
of the adult population has received at least one dose, authorities say.
Brazilians commonly claim with pride that the nation has a "cultura de
vacinacao," or "vaccine culture."
The same can be said for several other nations in the region, which have
previously launched expansive inoculation campaigns after traumatic
infectious disease outbreaks in recent decades.
"This confidence, built up over several years, is based on the benefits
of our extensive vaccination schedule," said Leda Guzzi, a Buenos
Aires-based infectious disease expert.
Effective public health messaging has been key, too, said Albert Ko, a
professor at the Yale School of Public Health and a collaborating
researcher at Rio de Janeiro's Oswaldo Cruz Foundation.
[to top of second column]
|

A healthcare worker takes a swab sample from a woman to be tested
for the coronavirus disease (COVID-19), at La Rural, in Buenos
Aires, Argentina December 23, 2021. REUTERS/Agustin Marcarian
 In Brazil, for instance, a mascot
resembling a docile white droplet, known as "Zé Gotinha," has been
heavily used by health officials to promote the vaccine, even as
President Jair Bolsonaro has himself declined to be jabbed.
Earlier this year, baile funk star MC Fioti released a viral video
with a modified version of one of his hits in association with the
Butantan biomedical institute in Sao Paulo promoting the vaccine.
STORM CLOUDS GATHER
The region, however, is far from out of the woods, particularly as
the Omicron variant spreads across the globe.
Even with an impressive 63.3% of the population vaccinated, the
region remains below the threshold that most scientists say is
needed to offer mass protection. Omicron is now raging in much of
Europe despite similar levels of inoculation.
Among children, vaccination rates also vary dramatically from
country to country in Latin America, with authorities in Mexico and
Brazil relatively slow to approve shots for minors.
Another potential issue is the vaccines used.
Many countries, such as Chile, Uruguay and Brazil, relied heavily on
Coronavac, a vaccine produced by China's Sinovac Biotech Ltd,
particularly in the initial phase of their vaccination drives.
While the vaccine is credited with getting jabs into arms quickly,
its efficacy is lower than that of its peers, and at least one
initial study has indicated it may not produce antibodies against
the Omicron variant. Earlier in December, the World Health
Organization (WHO) said that recipients of Sinovac - as well as all
other "inactivated" vaccines - should get boosted.
Epidemiologists also say, Omicron may be more adept at dodging the
immunity generated by previous COVID-19 infections. That could be
bad news in a region where the virus ripped through entire
neighborhoods in earlier stages of the pandemic.

"Many people, particularly in vulnerable communities in Brazil, have
been infected," said Ko, the Yale epidemiologist. "We see this virus
infecting people who had already gotten infected before."
(Reporting by Gram Slattery in Rio de Janeiro and Agustin Geist in
Buenos Aires, additional reporting by Diego Ore and Dave Graham in
Mexico City and Oliver Griffin in Bogota; Editing by Stephen
Eisenhammer and Aurora Ellis)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |